PTC Therapeutics, Inc.
PTCT
Kedudukan dalam Saham
#3484
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Harga Saham
$59.28
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$4.95B
Perubahan (1 hari)
-2.80%
Perubahan (1 tahun)
-10.11%
Negara
US
Perdagangan PTC Therapeutics, Inc. (PTCT)
Kategori
Healthcare
Margin Operasi untuk PTC Therapeutics, Inc. (PTCT)
Margin Operasi pada October 2026 TTM: 11.52%
Menurut laporan kewangan dan harga saham terkini PTC Therapeutics, Inc., margin operasi semasa (TTM) ialah 11.52%. Pada akhir 2023, margin operasi syarikat ialah -37.26%.
Sejarah Margin Operasi untuk PTC Therapeutics, Inc. dari 2011 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Ubah |
|---|---|---|
| 2026 (TTM) | 11.52% | -130.72% |
| 2024 | -37.50% | 0.64% |
| 2023 | -37.26% | -40.81% |
| 2022 | -62.95% | -9.58% |
| 2021 | -69.62% | -38.60% |
| 2020 | -113.39% | 80.56% |
| 2019 | -62.80% | 43.71% |
| 2018 | -43.70% | 32.14% |
| 2017 | -33.07% | -79.29% |
| 2016 | -159.67% | -64.88% |
| 2015 | -454.58% | 5.00% |
| 2014 | -432.93% | 198.74% |
| 2013 | -144.92% | 55.58% |
| 2012 | -93.15% | -401.46% |
| 2011 | 30.90% | 0.00% |
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat | Margin Operasi | Perbezaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -96.65% |
US
|
|
| -149.01% | -112.93% |
US
|
|
| 25.57% | -97.78% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -97.50% |
NL
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.